RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship

PURPOSE: In RELAY, ramucirumab plus erlotinib (RAM + ERL) improved progression-free survival (PFS) in patients with untreated, metastatic, EGFR-mutated, non-small cell lung cancer (NSCLC). Here, we present the exposure–response relationship of RAM from RELAY. METHODS: Patients received ERL (150 mg/d...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Kazuhiko, Garon, Edward B., Gao, Ling, Callies, Sophie, Zimmermann, Annamaria, Walgren, Richard, Visseren-Grul, Carla, Reck, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360106/
https://www.ncbi.nlm.nih.gov/pubmed/35841410
http://dx.doi.org/10.1007/s00280-022-04447-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9360106/
https://www.ncbi.nlm.nih.gov/pubmed/35841410
http://dx.doi.org/10.1007/s00280-022-04447-x

Ejemplares similares